title: Does vimentin help to delineate the so-called 'basal type breast cancer'?
abstract: BACKGROUND
  Vimentin is one of the cytoplasmic intermediate filament proteins which are the major component of the cytoskeleton. In our study we checked the usefulness of vimentin expression in identifying cases of breast cancer with poorer prognosis, by adding vimentin to the immunopanel consisting of basal type cytokeratins, estrogen, progesterone, and HER2 receptors.
  
  
  METHODS
  179 tissue specimens of invasive operable ductal breast cancer were assessed by the use of immunohistochemistry. The median follow-up period for censored cases was 90 months.
  
  
  RESULTS
  38 cases (21.2%) were identified as being vimentin-positive. Vimentin-positive tumours affected younger women (p = 0.024), usually lacked estrogen and progesterone receptor (p < 0.001), more often expressed basal cytokeratins (<0.001), and were high-grade cancers (p < 0.001). Survival analysis showed that vimentin did not help to delineate basal type phenotype in a triple negative (ER, PgR, HER2-negative) group. For patients with 'vimentin or CK5/6, 14, 17-positive' tumours, 5-year estimated survival rate was 78.6%, whereas for patients with 'vimentin, or CK5/6, 14, 17-negative' tumours it was 58.3% (log-rank p = 0.227).
  
  
  CONCLUSIONS
  We were not able to better delineate an immunohistochemical definition of basal type of breast cancer by adding vimentin to the immunopanel consisted of ER, PgR, HER2, CK5/6, 14 and 17 markers, when overall survival was a primary end-point.
authors.affiliation: Department of Pathology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland. renata.kusinska@gmail.com
authors.forename: Renata U
authors.initials: RU
authors.lastname: Kusinska
authors.forename: Radzislaw
authors.initials: R
authors.lastname: Kordek
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Pluciennik
authors.forename: Andrzej K
authors.initials: AK
authors.lastname: Bednarek
authors.forename: Janusz H
authors.initials: JH
authors.lastname: Piekarski
authors.forename: Piotr
authors.initials: P
authors.lastname: Potemski
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016019:Survival Analysis; D014746:Vimentin / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D014746:Vimentin
references.citation: Mod Pathol. 2008 Oct;21(10):1183-91
references.pmid: 18536655
references.citation: Pol J Pathol. 2005;56(3):107-10
references.pmid: 16334976
references.citation: Breast Cancer Res. 2007;9(6):404; author reply 405
references.pmid: 18279542
references.citation: Cancer Res. 2003 May 15;63(10):2658-64
references.pmid: 12750294
references.citation: Oncology. 2005;69(6):478-85
references.pmid: 16410686
references.citation: J Pathol. 2005 Aug;206(4):451-7
references.pmid: 15906273
references.citation: J Pathol. 1989 Apr;157(4):299-306
references.pmid: 2469782
references.citation: Mod Pathol. 2005 Oct;18(10):1321-8
references.pmid: 15990899
references.citation: Pathology. 2002 Jun;34(3):230-2
references.pmid: 12109782
references.citation: Am J Pathol. 1990 Nov;137(5):1143-55
references.pmid: 1700618
references.citation: Am J Pathol. 1990 Nov;137(5):1059-64
references.pmid: 2173410
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
references.pmid: 11553815
references.citation: Int J Cancer. 1996 Jul 29;67(3):353-6
references.pmid: 8707408
references.citation: Cancer Res. 1989 Aug 1;49(15):4258-63
references.pmid: 2472876
references.citation: Clin Cancer Res. 2009 Apr 1;15(7):2302-10
references.pmid: 19318481
references.citation: Breast Cancer Res. 2007;9(1):R16
references.pmid: 17263897
references.citation: Cancer Res. 2001 Jul 1;61(13):5168-78
references.pmid: 11431356
references.citation: Tumori. 2009 Jan-Feb;95(1):53-62
references.pmid: 19366057
references.citation: Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8
references.pmid: 12917485
references.citation: Breast Cancer Res. 2007;9(5):R65
references.pmid: 17910759
references.citation: Am J Pathol. 1990 Jan;136(1):219-27
references.pmid: 2153347
references.citation: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
references.pmid: 12829800
references.citation: Nature. 2000 Aug 17;406(6797):747-52
references.pmid: 10963602
references.citation: Am J Pathol. 1997 Feb;150(2):483-95
references.pmid: 9033265
references.citation: Cells Tissues Organs. 2007;185(1-3):191-203
references.pmid: 17587825
references.citation: J Pathol. 2004 Jun;203(2):661-71
references.pmid: 15141381
references.citation: Clin Cancer Res. 2004 Aug 15;10(16):5367-74
references.pmid: 15328174
references.citation: J Clin Pathol. 1993 May;46(5):441-5
references.pmid: 7686566
references.citation: Am J Pathol. 2002 Dec;161(6):1991-6
references.pmid: 12466114
references.citation: BMC Cancer. 2007 Jul 24;7:134
references.pmid: 17650314
references.citation: Arch Pathol Lab Med. 1985 Aug;109(8):716-21
references.pmid: 3893381
references.citation: Int J Oncol. 2004 Aug;25(2):249-58
references.pmid: 15254720
references.citation: Clin Cancer Res. 2008 Mar 1;14(5):1368-76
references.pmid: 18316557
references.citation: J Pathol. 1996 Oct;180(2):175-80
references.pmid: 8976877
references.citation: Am J Clin Pathol. 1987 Sep;88(3):286-96
references.pmid: 2443000